title: Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Raphael
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Morrissey
authors.forename: Ellen J
authors.initials: EJ
authors.lastname: Kim
authors.forename: Carmela C
authors.initials: CC
authors.lastname: Vittorio
authors.forename: Alain H
authors.initials: AH
authors.lastname: Rook
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011701:PUVA Therapy / Q000379:methods*; D018570:Risk Assessment; D012494:Sampling Studies; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents; D007166:Immunosuppressive Agents